412 related articles for article (PubMed ID: 30320114)
1. Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.
Zumelzu C; Alexandre M; Le Roux C; Weber P; Guyot A; Levy A; Aucouturier F; Mignot-Grootenboer S; Caux F; Maubec E; Prost-Squarcioni C
Front Med (Lausanne); 2018; 5():268. PubMed ID: 30320114
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.
Ványai B; Chien YC; Beke L; Szabó IL; Péter Z; Steuer-Hajdu K; Várvölgyi T; Méhes G; Emri G
Immunotherapy; 2022 Dec; 14(17):1377-1382. PubMed ID: 36475303
[TBL] [Abstract][Full Text] [Related]
3. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
Gaudin O; Seta V; Alexandre M; Bohelay G; Aucouturier F; Mignot-Grootenboer S; Ingen-Housz-Oro S; Bernardeschi C; Schneider P; Mellottee B; Caux F; Prost-Squarcioni C
Front Immunol; 2018; 9():1030. PubMed ID: 29881377
[TBL] [Abstract][Full Text] [Related]
4. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.
Tsiogka A; Bauer JW; Patsatsi A
Acta Derm Venereol; 2021 Jan; 101(1):adv00377. PubMed ID: 33426566
[TBL] [Abstract][Full Text] [Related]
5. Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.
Bohelay G; Alexandre M; Le Roux-Villet C; Sitbon I; Doan S; Soued I; Shourick J; Rousset L; Mellottee B; Heller M; Lièvre N; Zumelzu C; Morin F; Grootenboer-Mignot S; Gabison E; Caux F; Prost-Squarcioni C; Musette P
Front Immunol; 2022; 13():915205. PubMed ID: 35844526
[TBL] [Abstract][Full Text] [Related]
6. Laryngeal Mucous Membrane Pemphigoid as an Immune-related Adverse Effect of Pembrolizumab Treatment.
Lagos-Villaseca A; Koshkin VS; Kinet MJ; Rosen CA
J Voice; 2023 Jan; ():. PubMed ID: 36658034
[TBL] [Abstract][Full Text] [Related]
7. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
Cosimati A; Rossi L; Didona D; Forcella C; Didona B
J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.
Amber KT; Murrell DF; Schmidt E; Joly P; Borradori L
Clin Rev Allergy Immunol; 2018 Feb; 54(1):26-51. PubMed ID: 28779299
[TBL] [Abstract][Full Text] [Related]
9. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
10. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
Parakh S; Nguyen R; Opie JM; Andrews MC
Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
[TBL] [Abstract][Full Text] [Related]
11. Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports.
Thomsen K; Diernaes J; Øllegaard TH; Spaun E; Vestergaard C
Case Rep Dermatol; 2018; 10(2):154-157. PubMed ID: 30022934
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of oral mucous membrane pemphigoid and lichenoid drug reaction: a case of toripalimab-triggered and pembrolizumab-aggravated oral adverse events.
Duan S; Zhang X; Wang F; Shi Y; Wang J; Zeng X
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Sep; 132(3):e86-e91. PubMed ID: 34238713
[TBL] [Abstract][Full Text] [Related]
13. Mucous membrane pemphigoid-otorhinolaryngological manifestations: a retrospective cohort study.
Madgar O; Baniel A; Yarom N; Glikson E; Zeeli T; Sprecher E; Alon EE
Eur Arch Otorhinolaryngol; 2020 Mar; 277(3):939-945. PubMed ID: 31980882
[TBL] [Abstract][Full Text] [Related]
14. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
Rofe O; Bar-Sela G; Keidar Z; Sezin T; Sadik CD; Bergman R
Clin Exp Dermatol; 2017 Apr; 42(3):309-312. PubMed ID: 28211077
[TBL] [Abstract][Full Text] [Related]
15. A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report.
Gresham LM; Kirchhof MG
SAGE Open Med Case Rep; 2023; 11():2050313X231160926. PubMed ID: 36968984
[TBL] [Abstract][Full Text] [Related]
16. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
Lopez AT; Geskin L
Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
[TBL] [Abstract][Full Text] [Related]
17. A case report of bullous pemphigoid associated with a melanoma and review of the literature.
Amber KT; Panganiban CM; Korta D; Feraudy S; Kelly KM; Grando SA
Melanoma Res; 2017 Feb; 27(1):65-67. PubMed ID: 27759577
[TBL] [Abstract][Full Text] [Related]
18. A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication.
Bezinelli LM; Eduardo FP; Migliorati CA; Ferreira MH; Taranto P; Sales DB; Santi CG; Macarenco RS; Godoy CPV; Corrêa L; Buzaid AC
J Immunother; 2019; 42(9):359-362. PubMed ID: 31246641
[TBL] [Abstract][Full Text] [Related]
19. The Diagnosis and Blistering Mechanisms of Mucous Membrane Pemphigoid.
Kamaguchi M; Iwata H
Front Immunol; 2019; 10():34. PubMed ID: 30740099
[TBL] [Abstract][Full Text] [Related]
20. Immune-mediated subepithelial blistering diseases of mucous membranes. Pure ocular cicatricial pemphigoid is a unique clinical and immunopathological entity distinct from bullous pemphigoid and other subsets identified by antigenic specificity of autoantibodies.
Chan LS; Yancey KB; Hammerberg C; Soong HK; Regezi JA; Johnson K; Cooper KD
Arch Dermatol; 1993 Apr; 129(4):448-55. PubMed ID: 7682049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
